| Identified mutations (n) |
|---|
| NRTI | Accessory PI | NNRTI | Resistance level to EFVa |
|---|
| M184 (1) | T47S (7) | K103N (11) | High |
| | Q58E (4) | A98G (3) | High level resistance 3TC, Low level resistance EFV |
| | K20T (1) | V106M (2) | High |
| | M46L (1) | Y181C (7) | Intermediate |
| | M46V (1) | G190A (2) | Intermediate |
| | N88D (1) | K103S (1) | Intermediate |
| | | K238T (1) | Intermediate |
| | | H221Y (4) | Low |
| | | V108I (4) | Low |
| | | E138G (2) | Low |
| | | V179D (2) | Low |
| | | E138K (1) | Low |
| | | K101E (1) | Low |
- The total number of mutations reported is higher than the number of individual samples with NNRTI-DRMs, as many samples showed multiple mutations
- NRTI nucleoside/nucleotide reverse transcriptase inhibitors, PI protease inhibitors, NNRTI non-nucleoside reverse-transcriptase inhibitors, EFV efavirenz, 3TC lamivudine
- aAccording to the Stanford Drug Resistance Database
